Heart disease is more common in people over 65, but treatments are better than ever. That can complicate decision-making for older heart patients.
The dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk ...
Researchers at the University of Toronto's Institute of Biomedical Engineering have found that studying blood flow in leg ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback